Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Levocloperastine→

Levocloperastine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
132301-89-4
Molecular formula
C20H24ClNO
Molecular weight
329.9 g/mol
Drug class
Non-opioid antitussivecentral and peripheral cough-reflex suppressant
Mechanism of action
The levorotatory isomer of cloperastine. It has described central effects at the medullary cough centre and peripheral effects on tracheobronchial cough receptors. Mechanistic data remain limited; cloperastine also has antihistaminic and papaverine-like smooth-muscle effects.
Indications / reported uses
  • Symptomatic relief of non-productive cough associated with respiratory tract conditions in countries where levocloperastine-containing products are authorised.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11060423/ · https://pubmed.ncbi.nlm.nih.gov/?term=levocloperastine+clinical+trial · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Levocloperastine Environmental Risk Assessment (ERA) (the Levocloperastine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.